Current Issue : October - December Volume : 2019 Issue Number : 4 Articles : 5 Articles
This study evaluated the effects of alpha-s1 casein hydrolysate (ACH; Lactium®) on the\nsubjective and objective sleep profiles of a community-based sample of Koreans with poor sleep quality.\nWe performed a double-blind, randomized crossover trial with 48 participants (49.0 ....add/subs 1.7 years old,\n65% female) who exhibited a mild to moderate degree of sleep disturbance. Either ACH or placebo\nwas administered for the initial four weeks, and the counterpart was administered in precisely the\nsame manner after a four-week washout period. Sleep disturbance scales, daytime functioning,\nand psychiatric aspects showed a similar tendency to improve during both ACH and placebo\nphases without significant group differences. Overall perceived sleep profiles in sleep diaries were\nsignificantly improved during the ACH phase, represented by increased total sleep time and sleep\nefficiency (SE), as well as decreased sleep latency and wake after sleep onset (WASO). Interestingly,\nactigraphy demonstrated significantly increased SE after continuous use of ACH for four weeks,\nclearly more improved when compared to two weeks of use. The polysomnography measures\nshowed a similar tendency without statistically significant group diffierences. Our findings suggest\nthat refined ACH was well tolerated and could improve sleep quality, with possible cumulative\nbeneficial effects with long-term administration....
Background. Cardiac contractilitymodulation (CCM) is a device therapy for systolic heart failure (HF) in patientswith narrowQRS.\nWe aimed to perform an updated meta-analysis of the randomized clinical trials (RCTs) to assess the efficacy and safety of CCM\ntherapy. Methods. We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) between January 2001\nand June 2018. Outcomes of interest were peak oxygen consumption (peak VO2), 6-MinuteWalk Distance (6MWD), Minnesota\nLiving with Heart Failure Questionnaire (MLHFQ), HF hospitalizations, cardiac arrhythmias, pacemaker/ICD malfunctioning,\nall-cause hospitalizations, and mortality. Data were expressed as standardized mean difference (SMD) or odds ratio (OR). Results.\nFour RCTs including 801 patients (CCMn = 394) were available for analysis......................
This study aims to assess the effcacy and safety of doripenem on treating patients with\nacute bacterial infections. The Pubmed, Embase, and Cochrane databases were searched up to April\n2019. Only randomized clinical trials comparing doripenem and other comparators for the treatment\nof acute bacterial infection were included. The primary outcome was the clinical success rate and\nthe secondary outcomes were microbiological eradication rate and risk of adverse events. Eight\nrandomized controlled trials (RCTs) were included. Overall, doripenem had a similar clinical success\nrate with comparators (odds ratio [OR], 1.15; 95% CI, 0.79-1.66, I2 = 58%). Similar clinical success\nrates were noted between doripenem and comparators for pneumonia (OR, 0.84; 95% CI, 0.46-1.53,\nI^2 = 72%) and for intra-abdominal infections (OR, 1.00; 95% CI, 0.57-1.72). For complicated urinary\ntract infection, doripenem was associated with higher success rate than comparators (OR, 1.89, 95%\nCI, 1.13-3.17, I^2 = 0%). The pool analysis comparing doripenem and other carbapenems showed no\nsignificant differences between each other (OR, 0.96, 95% CI, 0.59-1.58, I^2 = 63%). Doripenem also\nhad a similar microbiological eradication rate with comparators (OR, 1.08; 95% CI, 0.86-1.36, I^2 = 0%).\nFinally, doripenem had a similar risk of treatment-emergent adverse events as comparators (OR, 0.98;\n95% CI, 0.83-1.17, I^2 = 33%). In conclusion, the clinical effcacy of doripenem is as high as that of the\ncomparator drugs in the treatment of acute bacterial infection; furthermore, this antibiotic is as well\ntolerated as the comparators....
This study aims to assess the clinical e_cacy and safety of eravacycline for treating\ncomplicated intra-abdominal infection (cIAI) in adult patients. The PubMed, Web of Science, EBSCO,\nCochrane databases, Ovid Medline, Embase, and ClinicalTrials.gov were searched up to May 2019.\nOnly randomized controlled trials (RCTs) that evaluated eravacycline and other comparators for the\ntreatment of cIAI were included. The primary outcome was the clinical cure rate at the test-of-cure\nvisit based on modified intent-to-treat population, microbiological intent-to-treat population, clinically\nevaluable population, and microbiological evaluable population, and the secondary outcomes were\nclinical failure rate and the risk of adverse event. Three RCTs were included. Overall, eravacycline\nhad a clinical cure rate (88.7%, 559/630) at test-of-cure in modified intent-to-treat population similar\nto comparators (90.1%, 492/546) in the treatment of cIAIs (risk ratio (RR), 0.99; 95% confidence\ninterval (CI), 0.95-1.03; I^2 = 0%, Figure 3). In the microbiological intent-to-treat, clinically evaluable,\nand microbiological evaluable populations, no difference was found between eravacycline and\ncomparators in terms of clinical cure rate at test-of-cure (microbiological intent-to-treat population,\nRR, 0.99; 95% CI, 0.95-1.04; I^2 = 0%, clinically evaluable population, RR, 1.00; 95% CI, 0.97-1.03; I^2 = 0%,\nmicrobiological evaluable population, RR, 0.98; 95% CI, 0.95-1.02; I^2 = 0%). In addition, eravacycline\nhad clinical failure rate similar to comparators at test-of-cure in modified intent-to-treat population (RR,\n1.01; 95% CI, 0.61-0.69; I^2 = 0%), microbiological intent-to-treat population (RR, 1.34; 95% CI, 0.77-2.31;\nI^2 = 16%), clinically evaluable population (RR, 1.03; 95% CI, 0.61-1.76; I^2 = 0%), and microbiological\nevaluable population (RR, 1.32; 95% CI, 0.75-2.32; I^2 = 10%). Although eravacycline was associated\nwith higher risk of treatment-emergent adverse event than comparators (RR, 1.34; 95% CI, 1.13-1.58;\nI^2 = 0%), no significant differences were found between eravacycline and comparators for the risk of\nserious adverse event (RR, 1.04; 95% CI, 0.65-1.65; I^2 = 0%), discontinuation of study drug because\nof adverse event (RR, 0.68; 95% CI, 0.23-1.99; I^2 = 13%), and all-cause mortality (RR, 1.09; 95%\nCI, 0.41-2.9; I^2 = 28%). In conclusion, the clinical efficacy of eravacycline is as high as that of the\ncomparator drugs in the treatment of cIAIs and this antibiotic is as well tolerated as the comparators....
Objective. To investigate the therapeutic potential and efficacy of Shinbaro, an herbal medication for inflammatory diseases and\nbone disorders, as a preventive treatment of migraine. Methods. In this prospective, interventional, single-arm, pre-post study,\n37 migraine patients took 600mg bid of Shinbaro for 12 weeks. At 4-week intervals, the migraine frequency and the rescue\nmedications frequency weremeasured fromeach patientâ??s headache diary. Themodified Migraine Disability Assessment (MIDAS)\nquestionnaires to assessmigraine associated disabilities were also completed at each visit.The serumcalcitonin gene-relatedpeptide\n(CGRP) concentrations before and after 12 weeks of Shinbaro administration were compared. ........................
Loading....